JNJ

225.57

+0.63%↑

UNH

363.82

-1.87%↓

TMO

466.62

+0.92%↑

ISRG

451.55

-0.21%↓

ABT

87.15

-0.47%↓

JNJ

225.57

+0.63%↑

UNH

363.82

-1.87%↓

TMO

466.62

+0.92%↑

ISRG

451.55

-0.21%↓

ABT

87.15

-0.47%↓

JNJ

225.57

+0.63%↑

UNH

363.82

-1.87%↓

TMO

466.62

+0.92%↑

ISRG

451.55

-0.21%↓

ABT

87.15

-0.47%↓

JNJ

225.57

+0.63%↑

UNH

363.82

-1.87%↓

TMO

466.62

+0.92%↑

ISRG

451.55

-0.21%↓

ABT

87.15

-0.47%↓

JNJ

225.57

+0.63%↑

UNH

363.82

-1.87%↓

TMO

466.62

+0.92%↑

ISRG

451.55

-0.21%↓

ABT

87.15

-0.47%↓

Sanofi

Затворен

43.37 0.18

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

43.08

Максимум

43.52

Ключови измерители

By Trading Economics

Приходи

2.4B

1.6B

Продажби

-961M

11B

P/E

Средно за сектора

19.885

67.147

EPS

1.102

Марж на печалбата

14.354

Служители

74,846

EBITDA

-1.1B

2.7B

Препоръки

By TipRanks

Препоръки

Неутрален

12-месечна прогноза

+22.26% upside

Пазарни показатели

By TradingEconomics

Пазарна капитализация

-11B

104B

Предишно отваряне

43.19

Предишно затваряне

43.37

Техническа оценка

By Trading Central

Увереност

Strong Bearish Evidence

Sanofi Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

23.04.2026 г., 06:12 ч. UTC

Печалби

Sanofi Posts Higher Sales Amid Leadership Transition

12.02.2026 г., 12:40 ч. UTC

Значими двигатели на пазара

Sanofi Shares Fall After CEO Change

29.01.2026 г., 11:35 ч. UTC

Печалби

Sanofi Remains Committed to Vaccines After Mixed Year for Drug Pipeline -- Update

29.04.2026 г., 12:01 ч. UTC

Печалби

Regeneron Earnings Beat Expectations. Upcoming Cancer Data Matter More for the Stock. -- Barrons.com

27.04.2026 г., 09:32 ч. UTC

Пазарно говорене
Печалби

Sanofi's Dupixent Sales Growth Set to Moderate -- Market Talk

27.04.2026 г., 09:19 ч. UTC

Пазарно говорене

Sanofi's New CEO Needs to Be Clear on Strategy -- Market Talk

23.04.2026 г., 05:34 ч. UTC

Печалби

Sanofi: 2026 Expectations Are at Constant Exchange Rates

23.04.2026 г., 05:34 ч. UTC

Печалби

Sanofi Sees Business EPS Growth Slightly Faster Than Sales in 2026

23.04.2026 г., 05:34 ч. UTC

Печалби

Sanofi Sees Sales Growth by a High Single-Digit Percentage in 2026

23.04.2026 г., 05:34 ч. UTC

Печалби

Sanofi Backs 2026 View

23.04.2026 г., 05:33 ч. UTC

Печалби

Sanofi 1Q Business Net Pft EUR2.26B

23.04.2026 г., 05:33 ч. UTC

Печалби

Analysts Saw Sanofi 1Q Business Oper Pft at EUR2.85B

23.04.2026 г., 05:33 ч. UTC

Печалби

Sanofi 1Q Business Oper Pft EUR2.97B

23.04.2026 г., 05:32 ч. UTC

Печалби

Analysts Saw Sanofi 1Q Net Sales at EUR10.22B

23.04.2026 г., 05:32 ч. UTC

Печалби

Sanofi 1Q Net Sales Rose 14% on Year at Constant Exchange Rates

23.04.2026 г., 05:31 ч. UTC

Печалби

Sanofi 1Q Net Sales EUR10.51B

10.04.2026 г., 11:12 ч. UTC

Пазарно говорене

Sanofi Investors Might Have to Wait for Update on Strategy -- Market Talk

10.04.2026 г., 10:54 ч. UTC

Пазарно говорене

Sanofi Could Get Boost From Dupixent U.S. Price -- Market Talk

30.03.2026 г., 10:40 ч. UTC

Пазарно говорене

Sanofi Shares Fall After Company Reports Second Cancer Case in Trial -- Market Talk

27.03.2026 г., 10:40 ч. UTC

Пазарно говорене

AstraZeneca Hits Goal in Lung Disease Where Rivals Missed -- Market Talk

11.03.2026 г., 11:02 ч. UTC

Пазарно говорене

Sanofi, Regeneron's Eczema Drug Might Face Competition From Pfizer -- Market Talk

24.02.2026 г., 14:00 ч. UTC

Придобивния, сливания и поглъщания

This Small-Cap Biotech Stock Is Soaring 35% on Excitement Over Its Prostate Cancer Drug -- Barrons.com

13.02.2026 г., 08:21 ч. UTC

Пазарно говорене

Sanofi's CEO Change Adds to Near-Term Uncertainty -- Market Talk

12.02.2026 г., 15:20 ч. UTC

Печалби

Sanofi Shares Fall After CEO Change -- Update

10.02.2026 г., 14:07 ч. UTC

Придобивния, сливания и поглъщания

Sanofi Set Out $2.2 Bln Cash Deal for Dynavax Late Last Year

10.02.2026 г., 14:06 ч. UTC

Придобивния, сливания и поглъщания

Sanofi: Acquisition Includes Dynavax's Hepatitis B Vaccine, Shingles Vaccine Candidate

10.02.2026 г., 14:05 ч. UTC

Придобивния, сливания и поглъщания

Sanofi Completes Acquisition of Dynavax

10.02.2026 г., 14:00 ч. UTC

Придобивния, сливания и поглъщания

Press Release: Sanofi Completes The Acquisition Of Dynavax >SAN.FR

6.02.2026 г., 12:35 ч. UTC

Печалби

Biogen Stock Rises Even as Multiple Sclerosis Revenue Tumbles. It Sees Continued Declines in the Portfolio. -- Barrons.com

29.01.2026 г., 13:00 ч. UTC

Пазарно говорене
Печалби

Sanofi Results Encourage, But Pipeline Strategy Should Take Priority -- Market Talk

Сравнение с други в отрасъла

Ценова промяна

Sanofi Прогноза

Ценова цел

By TipRanks

22.26% нагоре

12-месечна прогноза

Среден 53 USD  22.26%

Висок 57 USD

Нисък 50 USD

Според 3 анализатори от Wall Street, предложили 12-месечна ценова цел за Sanofi през последните три месеца.

Консенсусна оценка

By TipRanks

Неутрален

3 ratings

0

Купи

3

Задържане

0

Продай

Техническа оценка

By Trading Central

51.665 / 52.38Подкрепа & съпротива

Краткосрочен план

Strong Bearish Evidence

Средносрочен план

Weak Bullish Evidence

Дългосрочен план

Bullish Evidence

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products. In addition, it offers poliomyelitis, pertussis, and hib pediatric vaccines; influenza, booster, meningitis, and travel and endemic vaccines, which includes hepatitis A, typhoid, cholera, yellow fever, and rabies vaccines. The company also provides cough, cold, and flu, allergy, and pain care products, as well as physical, mental, and digestive wellness products; and offers products for itching, hydration, aging, cracking, overnight, and specialty skincare needs like eczema. Further, it has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301, a treatment for alpha-synucleinopathies; Blackstone Life Sciences to develop pivotal studies and clinical development program; and Seagen Inc. to design, develop, and commercialize antibody-drug conjugates for cancer. Additionally, the company has a collaboration agreement with IGM Biosciences, Inc. to develop, manufacture, and commercialize IgM antibody; Skyhawk Therapeutics, Inc to discover and develop novel small molecules; and Adagene Inc., for the discovery and development of antibody-based therapies. It also has collaborations with Scribe Therapeutics Inc. to develop genome editing technologies; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.
help-icon Live chat